Keyword: Seqirus

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.

Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.

A group of pediatric experts has recommended injected vaccines over AstraZeneca's FluMist for the upcoming season.

CSL's flu vaccine unit Seqirus posted $1.09 billion in sales during its 2018 fiscal year and turned in its first-ever profit.

Seqirus expects to offer 50 million flu vaccine doses, while GSK plans to boost its supplies to 40 million to 45 million, its highest total ever.

Seqirus has teamed up with the Human Vaccines Project's UIVI to advance universal flu vaccine development.

Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.

Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.